The $15M registered direct offering at $3.43 per share is highly dilutive (~20%) for a $98M market cap clinical-stage biotech. Monitor for cash runway extension metrics and Phase 1 trial catalysts for ELI-002 7P in metastatic PDAC. The 30-day lock-up expiration on August 5, 2026, could create overhang. No other financing or cross-filings were provided to contextualize urgency.
Price Chart
Executive Summary
Elicio Therapeutics announced a $15 million registered direct offering, issuing 4,380,313 shares at $3.43 per share to institutional investors. The net proceeds will fund Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, pipeline programs, and general corporate purposes. The offering is dilutive to existing shareholders by ~20% based on pre-offering share count and is expected to close on July 6, 2026.
Key Facts
- Offering of 4,380,313 shares at $3.43 per share for $15 million gross proceeds
- Post-offering minimum outstanding shares of 26,281,882 implies ~20% dilution from pre-offering base
- Used S-3 shelf registration declared effective March 16, 2026
- Lock-up agreements with CEO, directors, and certain shareholders for 30 days post-closing
- 30-day restriction on further equity issuance or registration
- Proceeds to fund Phase 1 for ELI-002 7P in metastatic PDAC and pipeline/platform
- Placement agents fees: 7% of gross proceeds (~$1.05M) plus $75k expense allowance
- Closing expected July 6, 2026 subject to customary conditions
Financial Impact
$15M gross proceeds / ~$13.9M estimated net proceeds after ~7% placement fee and expenses; ~20% dilution to existing shareholders
Risk Factors
- Significant dilution (~20%) from the offering may pressure the stock price near-term
- Clinical-stage biotech with no approved products — Phase 1 trial startup risk for ELI-002 7P
- 30-day lock-up expiration after July 6 close could lead to selling pressure in August
- Likely standing on Nasdaq with low market cap — further equity needs may arise
- Competitive KRAS-targeted immunotherapy landscape (e.g., Amgen, Mirati)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080058 |
| Document: tm2619637d1_ex10-2.htm | 0001104659-26-080058 |
| Document: tm2619637d1_8k.htm | 0001104659-26-080058 |
| Document: tm2619637d1_ex99-1.htm | 0001104659-26-080058 |
| Document: tm2619637d1_ex5-1.htm | 0001104659-26-080058 |
| Document: 0001104659-26-080058-index-headers.html | 0001104659-26-080058 |
| Document: 0001104659-26-080058-index.html | 0001104659-26-080058 |
| Document: 0001104659-26-080058.txt | 0001104659-26-080058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.70 (−9.57%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.70 (−9.09%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.70 (−54.67%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.70 (−63.91%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.70 (−83.89%) |
Mar 17, 2026 31w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.70 (−86.04%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.70 (−86.07%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.70 (+86.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers